ERBB2 and triple-negative breast carcinoma: For patients with stage II or III, their BMFS were not statistically different from that of stage I. Univariate analysis showed shorter BMFS for HER2-positive and triple-negative breast cancers, but multivariate analysis showed that only triple-negative subtypes were independent risk factors for BMFS (HR, 2.06 [95% CI, 1.35–3.14], Figure 1B).